Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials

BACKGROUND: Zoledronic acid (ZOL) is an important component of therapy for patients with metastatic bone disease (MBD) to reduce the risk of skeletal-related events (SREs). We evaluated overall survival (OS) in patients with MBD secondary to solid tumours included in placebocontrolled ZOL trials. PA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Bone Oncol
Hauptverfasser: Coleman, Robert E., Lipton, Allan, Costa, Luis, Cook, Richard J., Lee, Ker-Ai, Saad, Fred, Brown, Janet E., Terpos, Evangelos, Major, Pierre P., Kohno, Norio, Smith, Matthew, Body, Jean-Jacques
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2013
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723367/
https://ncbi.nlm.nih.gov/pubmed/26909273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2013.01.002
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge